Savior Lifetec Corporation
Research Savior Lifetec Corporation (4167.TWO) on Bullrun: market cap TWD 7.23B, P/E 7.4, dividend yield 4.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4167.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyTWD
- Market capTWD 7.23B
- P/E7.4
- Dividend yield4.2%
- Financial periodQ2 2026
- RevenueTWD 285.94M
- Net incomeTWD 772.65M
- Free cash flow-TWD 155.41M
- Gross margin36.7%
Valuation Snapshot
latest market cap is TWD 7.23B; P/E is 7.4; dividend yield is 4.2%.
Peer valuation comparison
Latest P/E is 7.44x versus a Healthcare sector median of 21.8x (65.9% below).
Latest dividend yield is 4.18% versus a Healthcare sector median of 2.4% (74.2% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 7.23B | 7.4 | 3.7% | 0.8 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.8 TWD, yield 4.2%.
About Savior Lifetec Corporation
Savior Lifetec Corporation engages in the research, development, design, manufacture, and sale of carbapenem generics in the Americas, Asia, Taiwan, Europe, and internationally. The company offers injection generics, controlled-release generics, the development of new dosage forms and drugs, and the APIs, excipients, intermediates, and dosage forms. It also provides medicine manufacturer technology and services. In addition, the company sells antibacterial raw materials and injectables.
ETFs that hold Savior Lifetec Corporation
US-listed ETFs
Savior Lifetec Corporation is held by 15 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Avantis Emerging Markets Equity ETF (AVEM) | <0.01% | 0.33% |
| Vanguard FTSE All-World ex-US Small-Cap Index Fund ETF Shares (VSS) | <0.01% | 0.06% |
| Dimensional Emerging Core Equity Market ETF (DFAE) | <0.01% | 0.29% |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | <0.01% | 0.39% |
| Dimensional World ex U.S. Core Equity 2 ETF (DFAX) | <0.01% | 0.28% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Savior Lifetec Corporation's market cap?
Savior Lifetec Corporation's market capitalization is TWD 7.23B.
What is Savior Lifetec Corporation's P/E ratio?
Savior Lifetec Corporation's price-to-earnings (P/E) ratio is 7.4.
Does Savior Lifetec Corporation pay a dividend?
Savior Lifetec Corporation has a dividend yield of 4.2%.
What does Savior Lifetec Corporation do?
Savior Lifetec Corporation engages in the research, development, design, manufacture, and sale of carbapenem generics in the Americas, Asia, Taiwan, Europe, and internationally. The company offers injection generics, controlled-release generics, the development of new dosage forms and drugs, and the APIs, excipients, intermediates, and dosage forms. It also provides medicine manufacturer technology and services. In addition, the company sells antibacterial raw materials and injectables. Savior Lifetec Corporation was founded in 1993 and is headquartered in Tainan City, Taiwan.